Loading...
•
Sep 30, 2022
Longeveron Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022.
Key Takeaways
Longeveron Inc. reported revenue of $0.3 million and a net loss of $5.2 million for the third quarter ended September 30, 2022. The company's cash and short-term investments were $22.3 million as of September 30, 2022.
FDA granted Fast Track Designation to Lomecel-B for infants with Hypoplastic Left Heart Syndrome (HLHS).
Completed enrollment in Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease.
All approvals in place to initiate enrollment in phase 2 trial for Aging Frailty in Japan.
Existing cash and short-term investments will be sufficient to cover expenses and capital requirements into the first half of 2024.
Forward Guidance
Based on the current operating plan and financial resources, existing cash and short-term investments will be sufficient to cover expenses and capital requirements into the first half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...